Literature DB >> 2795003

Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-brain barrier of an in situ perfused guinea-pig brain.

B V Zlokovic1, J B Mackic, B Djuricic, H Davson.   

Abstract

The uptake of enkephalin-(5-L-leucine) (Leu-enkephalin) at the luminal side of the blood-brain barrier was measured by means of an in situ vascular brain perfusion technique in the anaesthetized guinea pig. This method allows measurements of cerebrovascular peptide uptake over periods of up to 20 min, and excludes the solute under study from the general circulation and systemic metabolic influences. A capillary unidirectional transfer constant, Kin, for [tyrosyl-3,5-3H]Leu-enkephalin was estimated graphically from the multiple-time brain uptake data in the presence of different concentrations of unlabelled peptide, and dose-dependent self-inhibition was demonstrated. Analysis of unidirectional influx of blood-borne Leu-enkephalin into the brain revealed Michaelis-Menten saturation kinetics in the parietal cortex, caudate nucleus, and hippocampus, with Vmax between 0.14 and 0.16 nmol min-1 g-1 and Km ranging from 34 to 41 microM, for the saturable component, whereas the estimated diffusion constant, Kd, was not significantly different from zero. Entry of [3H]Leu-enkephalin was not inhibited in the presence of either a 5 mM concentration of unlabelled L-tyrosine, tyrosylglycine, and tyrosylglycylglycine, or aminopeptidase inhibitor, bestatin (0.5 mM), suggesting that the saturable mechanism of the tracer at the luminal side of the blood-brain barrier does not involve uptake of the peptide's N-terminal amino acid and/or its tyrosine-containing fragments.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795003     DOI: 10.1111/j.1471-4159.1989.tb08522.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

1.  A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.

Authors:  Rashid Deane; Itender Singh; Abhay P Sagare; Robert D Bell; Nathan T Ross; Barbra LaRue; Rachal Love; Sheldon Perry; Nicole Paquette; Richard J Deane; Meenakshisundaram Thiyagarajan; Troy Zarcone; Gunter Fritz; Alan E Friedman; Benjamin L Miller; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

Review 2.  Peripheral modulation of learning and memory: enkephalins as a model system.

Authors:  G Schulteis; J L Martinez
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

Review 4.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

Review 5.  The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.

Authors:  R Deane; A Sagare; B V Zlokovic
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 6.  Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier.

Authors:  B V Zlokovic
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

7.  Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.

Authors:  Abhay P Sagare; Rashid Deane; Henrik Zetterberg; Anders Wallin; Kaj Blennow; Berislav V Zlokovic
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 8.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Authors:  R Deane; R D Bell; A Sagare; B V Zlokovic
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

Review 9.  New therapeutic targets in the neurovascular pathway in Alzheimer's disease.

Authors:  Berislav V Zlokovic
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

10.  Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier.

Authors:  Rashid Deane; Barbra LaRue; Abhay P Sagare; Francis J Castellino; Zhihui Zhong; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2008-10-08       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.